{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:25:03Z","timestamp":1787127903513,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preformed donor-specific anti-HLA antibodies (DSA) are a major risk factor for antibody-mediated rejection and graft failure in kidney, heart, lung, and other vascularized solid organ transplants. Their clinical significance in pancreatic islet transplantation, however, remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a SANRA-guided narrative review using a focused PubMed search (January 1, 2000, to June 9, 2026) supplemented by citation chasing. Of 104 records identified, 11 directly evaluating islet transplantation formed the core evidence base, complemented by 38 references providing mechanistic, immunologic, and solid-organ context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The available islet-specific evidence is dominated by small single-center studies, registry analyses, and case series, with few reports directly evaluating preformed DSA. Across these reports, preformed DSA have not shown the consistent adverse effect expected from kidney transplantation, but the evidence is insufficient to establish safety. In the largest focused cohort, Piemonti et\u00a0al. reported no clear association between preformed DSA and graft failure, whereas post-transplant antibody evolution was more closely linked to impaired graft survival. Brooks et\u00a0al. similarly found rapid graft dysfunction after\n                      <jats:italic>de novo<\/jats:italic>\n                      DSA, while Pouliquen et\u00a0al. observed late\n                      <jats:italic>de novo<\/jats:italic>\n                      DSA without uniform graft loss. Registry and failure cohorts show that post-transplant allosensitization is clinically important, especially after immunosuppression withdrawal or repeat transplantation. A proposed mechanistic model is that portal infusion, low tissue mass, early instant blood-mediated inflammatory reaction, endothelial replacement, and non-vascularized graft architecture may reduce the immediate impact of pre-existing DSA while leaving the graft vulnerable to evolving humoral memory.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The limited evidence is insufficient to support a universal policy of automatic exclusion of otherwise suitable islet candidates solely because of low-level preformed DSA; nor does it establish that such antibodies are safe. Because the evidence derives mainly from small single-center cohorts, registry analyses, and case series, this conclusion is provisional and may not be generalized across programs.\n                      <jats:italic>De novo<\/jats:italic>\n                      DSA represent a distinct post-transplant risk and may be a more clinically informative warning signal. Standardized MFI interpretation, complement-binding assays, longitudinal monitoring, and harmonized outcomes are needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1909238","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T09:50:06Z","timestamp":1786528206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of preformed donor-specific anti-HLA antibodies on pancreatic islet transplantation outcomes: do they matter as they do in solid organ transplantation?"],"prefix":"10.3389","volume":"17","author":[{"given":"Ibrahim","family":"Tawhari","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, King Khalid University","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmah","family":"Yamani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, King Faisal Specialist Hospital & Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Umm Al-Qura University","place":["Mecca, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesfer","family":"Aldosari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, King Khalid University","place":["Abha, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"El Hennawy","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Transplantation, King Abdulaziz Medical City, Ministry of National Guard Health Affairs","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Tawhari","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]},{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Medicine, Division of Nephrology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","volume-title":"Idf Diabetes Atlas","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.7.2060","article-title":"Five-year follow-up after clinical islet transplantation","volume":"54","author":"Ryan","year":"2005","journal-title":"Diabetes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0063","article-title":"Improvement in outcomes of clinical islet transplantation: 1999-2010","volume":"35","author":"Barton","year":"2012","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05804-4","article-title":"Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry","volume":"66","author":"Hering","year":"2023","journal-title":"Diabetologia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S2213-8587(23)00082-7","article-title":"Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry","volume":"11","author":"Chetboun","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30078-0","article-title":"Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation: the TRIMECO randomized controlled trial","volume":"6","author":"Lablanche","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31334-0","article-title":"Advances in beta-cell replacement therapy for the treatment of type 1 diabetes","volume":"394","author":"Vantyghem","year":"2019","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16637","article-title":"Ten-year outcomes of islet transplantation in patients with type 1 diabetes: data from the Swiss-French GRAGIL network","volume":"21","author":"Lablanche","year":"2021","journal-title":"Am J Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00114-0","article-title":"Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada","volume":"10","author":"Marfil-Garza","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B13","volume-title":"FDA approves first cellular therapy to treat patients with type 1 diabetes","year":"2023"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.10.1907","article-title":"Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation","volume":"48","author":"Bennet","year":"1999","journal-title":"Diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)12020-4","article-title":"Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation","volume":"360","author":"Moberg","year":"2002","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e32834c2393","article-title":"Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment","volume":"16","author":"Nilsson","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12558","article-title":"Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation","volume":"14","author":"Naziruddin","year":"2014","journal-title":"Am J Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1258","article-title":"Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes","volume":"62","author":"Piemonti","year":"2013","journal-title":"Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13407","article-title":"De novo donor-specific HLA antibodies are associated with rapid loss of graft function following islet transplantation in type 1 diabetes","volume":"15","author":"Brooks","year":"2015","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13936","article-title":"Anti-donor HLA antibody response after pancreatic islet grafting: characteristics, risk factors, and impact on graft function","volume":"17","author":"Pouliquen","year":"2017","journal-title":"Am J Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003635","article-title":"Long-term persistence of allosensitization after islet allograft failure","volume":"105","author":"Rios","year":"2021","journal-title":"Transplantation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12463","DOI":"10.1038\/s41598-022-16782-3","article-title":"The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series","volume":"12","author":"Maanaoui","year":"2022","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.09.065","article-title":"Development of anti-human leukocyte antigen class 1 antibodies following allogeneic islet cell transplantation","volume":"37","author":"Lobo","year":"2005","journal-title":"Transplant Proc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000164143.22287.e3","article-title":"Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients","volume":"80","author":"van Kampen","year":"2005","journal-title":"Transplantation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000290388.70019.6e","article-title":"Allosensitization of islet allograft recipients","volume":"84","author":"Cardani","year":"2007","journal-title":"Transplantation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31817ba628","article-title":"Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation","volume":"86","author":"Ferrari-Lacraz","year":"2008","journal-title":"Transplantation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3727\/096368911X612468","article-title":"HLA class I sensitization in islet transplant recipients: report from the Collaborative Islet Transplant Registry","volume":"21","author":"Naziruddin","year":"2012","journal-title":"Cell Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02479.x","article-title":"Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation","volume":"9","author":"Huurman","year":"2009","journal-title":"Am J Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002435","article-title":"Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation","volume":"3","author":"Huurman","year":"2008","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg1046","article-title":"Inverted direct allorecognition triggers early donor-specific antibody responses after transplantation","volume":"14","author":"Charmetant","year":"2022","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.05.035","article-title":"Diagnosis and treatment of allograft rejection in islet transplantation","volume":"23","author":"Landstra","year":"2023","journal-title":"Am J Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93542","article-title":"Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15937","article-title":"Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report","volume":"20","author":"Tambur","year":"2020","journal-title":"Am J Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1164\/rccm.201509-1857OC","article-title":"De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation","volume":"194","author":"Tikkanen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2018.05.002","article-title":"The clinical impact of donor-specific antibodies in heart transplantation","volume":"32","author":"Barten","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02711.x","article-title":"Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and intravenous immunoglobulin therapy","volume":"9","author":"Kessler","year":"2009","journal-title":"Am J Transplant"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16174","article-title":"Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes","volume":"21","author":"Markmann","year":"2021","journal-title":"Am J Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2023.04.002","article-title":"Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes","volume":"30","author":"Hogrebe","year":"2023","journal-title":"Cell Stem Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2506549","article-title":"Stem cell-derived, fully differentiated islets for type 1 diabetes","volume":"393","author":"Reichman","year":"2025","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02055-5","article-title":"Encapsulated stem cell-derived beta cells exert glucose control in patients with type 1 diabetes","volume":"42","author":"Keymeulen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00957.x","article-title":"Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience","volume":"5","author":"Froud","year":"2005","journal-title":"Am J Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03073.x","article-title":"Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab","volume":"10","author":"Posselt","year":"2010","journal-title":"Am J Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13138","article-title":"Defining outcomes for beta-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA\/EPITA opinion leaders workshop","volume":"31","author":"Rickels","year":"2018","journal-title":"Transpl Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1909238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:33:22Z","timestamp":1787124802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1909238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1909238"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1909238","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1909238"}}